NCT02086045View on ClinicalTrials.gov

Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial

NACompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

May 15, 2017

Conditions
Coronary Artery Disease
Interventions
DEVICE

DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System

percutaneous coronary

Trial Locations (13)

1023

Auckland City Hospital, Auckland

Mercy Angiography Unit, Auckland

2020

AZ Middelheim Hospital, Antwerp

8200

Aarhus University Hospital, Skejby, Aarhus N

12203

Charite - Campus Benjamin Franklin, Berlin

22527

Universitäres Herz- und Gefäßzentrum, Hamburg

B-3600

St. - Jan Ziekenhuis Z.O.L., Genk

0401210

Instituto Dante Pazzanese, São Paulo

38400-368

ICT / Instituto Do Coracao Do Triangulo Mineiro, Uberlândia

0622

North Shore Hospital, Auckland

43-300

Polsko-Amerykańskie Kliniki Serca, Dąbrowa Górnicza

31-202

Centrum Interwencyjnego Leczenia Chorób Serca, Krakow

31-501

Jagiellonian University, Krakow

Sponsors
All Listed Sponsors
lead

Elixir Medical Corporation

INDUSTRY

NCT02086045 - Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial | Biotech Hunter | Biotech Hunter